

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



INNOCARE

诺 诚 健 华

InnoCare Pharma Limited

諾誠健華醫藥有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9969)

APPOINTMENT OF JOINT COMPANY SECRETARY AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

I. APPOINTMENT OF JOINT COMPANY SECRETARY

The board (the “**Board**”) of directors (the “**Directors**”) of InnoCare Pharma Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) hereby announces that Ms. Yuan Bei (袁蓓) (“**Ms. Yuan**”), senior director of investor relations of the Company, has been appointed as one of the joint company secretaries of the Company (the “**Joint Company Secretary**”) with effect from 5 June, 2026, and the company secretary of the Company, Ms. Lin Sio Ngo (“**Ms. Lin**”), will continue to serve as the other Joint Company Secretary.

The biographical details of Ms. Yuan and Ms. Lin are set out below:

Ms. Yuan joined the Company in May 2015 and served as executive assistant to the CEO of the Company. The Company’s RMB shares were listed on the Science and Technology Innovation Board (the “**STAR Market**”) of the Shanghai Stock Exchange in September 2022, since then she also acts as the director of investor relations and as the domestic information disclosure representative for the STAR Market (科創板境內信息披露代表) of the Company. She was promoted to senior director of investor relations in April 2026. Ms. Yuan is experienced in managing the affairs of the Board office, handling investor relationships, information disclosures, corporate governance and compliance with the Rules Governing the Listing of Securities (the “**Listing Rules**”) on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the STAR Market requirements.

Prior to joining the Company, Ms. Yuan worked in Coyote Bioscience Co., Ltd. (卡尤迪生物科技(北京)有限公司) from July 2013 to May 2015 as assistant to the CEO and project manager, mainly responsible for the financial and cooperation with the key clients.

Ms. Yuan graduated from Jilin Agricultural University (吉林農業大學) with a bachelor's degree in biotechnology major in 2010 and Biotechnology Research Institute (BRI) of Chinese Academy of Agricultural Sciences (中國農業科學院生物技術研究所) with a master's degree in biochemistry and molecular biology in June 2013. She holds the board secretary qualification certificate from the STAR MARKET.

Ms. Lin is a manager of SWCS Corporate Services Group (Hong Kong) Limited, a professional service provider specializing in corporate services. Ms. Lin has over 20 years of working experience in corporate secretarial and administration management areas. Ms. Lin has been an associate member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute since 2004. Ms. Lin holds a bachelor's degree in business administration and a master's degree in corporate governance.

II. WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES

Pursuant to Rule 8.17 of the Listing Rules, an issuer must appoint a company secretary who satisfies the requirements under Rule 3.28 of the Listing Rules. Rule 3.28 of the Listing Rules provides that an issuer must appoint as its company secretary an individual who, in the opinion of the Stock Exchange, is capable of discharging the functions of a company secretary by virtue of his/her academic or professional qualifications or relevant experience.

Although Ms. Yuan does not possess the qualifications set out in Rule 3.28 of the Listing Rules, the Company proposes to appoint her as a joint company secretary of the Company in consideration of, among others, (i) her length of employment with the Company of more than 10 years; (ii) her in-depth understanding of the Company's business and familiarity with daily operations of the Board acquired during her work in overseeing the Board Office, organizing and arranging Board meetings, general meetings and major corporate events which enables her to efficiently coordinate work across various departments within the group; and (iii) her experience with corporate governance and knowledge of the Listing Rules of The Stock Exchange and the STAR Market of the Shanghai Stock Exchange acquired from her close involvement in the Company's respective listings on the Stock Exchange and the STAR Market, and major corporate events such as pre-IPO financing, ESG report compilation.

The Board believes that Ms. Yuan is a suitable candidate to act as a Joint Company Secretary and believes that her appointment is in the interest of the Company and will facilitate corporate governance and on-going compliance with the Listing Rules.

After the appointment of Ms. Yuan, Ms. Lin, who meets the qualification requirements under Note 1 to Rule 3.28 of the Listing Rules, and the current company secretary of the Company, will be redesignated as a Joint Company Secretary to work closely with and assist Ms. Yuan in enabling her to acquire the relevant company secretary experience as required under Rule 3.28 of the Listing Rules and to become familiar with the requirements of the Listing Rules and other applicable Hong Kong laws and regulations. In addition, Ms. Yuan will attend relevant professional training during each financial year as required under Rule 3.29 of the Listing Rules.

Accordingly, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted a waiver (the “**Waiver**”) to the Company from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for a period of three years from the date of appointment of Ms. Yuan as a joint company secretary of the Company (i.e. from 5 June, 2026 to 4 June, 2029) (the “**Waiver Period**”) on the conditions that:

- (i) Ms. Yuan must be assisted by Ms. Lin during the Waiver Period; and
- (ii) the Waiver could be revoked if there is any material breach of the Listing Rules by the Company.

Before the end of the Waiver Period, the Company must demonstrate and seek the confirmation from the Stock Exchange that Ms. Yuan, having had the benefit of Ms. Lin’s assistance during the Waiver Period, has attained the relevant experience and is capable of discharging the functions of a company secretary under Rule 3.28 of the Listing Rules such that a further waiver will not be necessary.

The Waiver applies to this appointment only. The Stock Exchange may withdraw or change the Waiver if the Company’s situation changes.

The Board would like to take this opportunity to express its welcome to Ms. Yuan on her appointment as the Joint Company Secretary.

By order of the Board
InnoCare Pharma Limited
Dr. Jisong Cui
Chairperson and Executive Director

Hong Kong, 5 June, 2026

As at the date of this announcement, the Board comprises Dr. Jisong Cui as Chairperson and executive Director, Dr. Renbin Zhao as executive Director, Dr. Yigong Shi and Mr. Ronggang Xie as non-executive Directors, and Ms. Lan Hu, Dr. Dandan Dong and Prof. Kunliang Guan as independent non-executive Directors.